Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity.
about
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infectionThe role of drug transporters in the kidney: lessons from tenofovirBrief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsHepatitis B virus: new therapeutic perspectives.Search for a cure for chronic hepatitis B infection: How close are we?Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.Towards the elimination and eradication of hepatitis B.Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsSafety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis.The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.Hepatitis B: Working Towards a Cure.Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients.Review article: novel therapies for hepatitis B virus cure - advances and perspectives.Tenofovir Alafenamide.Emtricitabine + tenofovir alafenamide for the treatment of HIV.Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.Renal Drug Transporters and Drug Interactions.Tenofovir Alafenamide: A Review in Chronic Hepatitis B.Atazanavir sulfate + cobicistat for the treatment of HIV infection.Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India.
P2860
Q26750406-8213A351-F59C-4216-9169-08890CE755C1Q26866489-BB1A08E5-F738-408E-9C09-CC33EE4E1017Q33669829-7A3D412B-FE45-48ED-A0B1-215CD8F123C6Q34507250-8B882330-E4E1-4875-A132-80918310E351Q35626790-7C9AA77D-51EC-48DF-9D6A-83EEA1E20B4AQ36663586-AA2118B1-E2E1-4835-9EC0-154000E0BAF6Q37098214-2D3F1A52-68BD-4153-9BDA-B7C9FCA75991Q37242504-A7632EFB-4B70-45BB-8F8F-3FE79F4C6C0DQ37354871-2F021548-AF76-496B-843F-2A9FD854F4F4Q37582471-00F9791E-D397-49CB-94E0-D9D59F5FE658Q37582474-FE7CA0DE-9BBC-4F86-96D0-062836F1E473Q37743012-3AD89F39-29CB-45F8-AD4E-769149829AFEQ38520954-BC71C9A7-4339-4BAE-A3CC-C2D23DBF2848Q38566984-E6740C5C-A233-45F7-934B-653586393F5CQ38661064-739BC0E6-30B5-4765-97A4-14639AC45916Q38802093-DE9D047D-50C0-4DF7-B705-88C7DF35C1B8Q38836878-DFC7C8B8-B55E-45DE-9BD9-311DA9ED81F6Q38839020-35F65841-A0A5-49D5-BC61-9C549D6F9090Q38865511-D87E3036-ABDB-4F34-8186-E5D084777AE6Q38910661-6288AF2F-B019-4388-9277-DEB84700A325Q38984695-6CE45088-7936-4030-A9B5-2E1D96F9323EQ39002230-88213C95-4EB4-49AB-AAAB-FF88D57B57E0Q39140289-1207EFC8-BA64-4262-B61A-AB9355293FE3Q39298139-6718A98C-9887-4E58-B55C-AAD25B13E1D3Q40237526-1E833451-DEE1-4395-B9D1-CF275C259AC0Q43882622-C50DE9DC-491A-4C13-B6F6-F2FFA71F5368Q45334368-F10AC3DF-4DA3-421F-AD9A-B182D74D676DQ50059498-D55511EE-A8F3-4DF1-B526-C25AB2B34057Q52641469-78ED2830-3E60-46DE-874C-7B9A4B502934
P2860
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Tenofovir alafenamide is not a ...... it OAT-dependent cytotoxicity.
@en
Tenofovir alafenamide is not a substrate for renal organic anion transporters
@nl
type
label
Tenofovir alafenamide is not a ...... it OAT-dependent cytotoxicity.
@en
Tenofovir alafenamide is not a substrate for renal organic anion transporters
@nl
prefLabel
Tenofovir alafenamide is not a ...... it OAT-dependent cytotoxicity.
@en
Tenofovir alafenamide is not a substrate for renal organic anion transporters
@nl
P356
P1433
P1476
Tenofovir alafenamide is not a ...... it OAT-dependent cytotoxicity.
@en
P2093
Rujuta A Bam
Stephen R Yant
P304
P356
10.3851/IMP2770
P50
P577
2014-04-04T00:00:00Z